| Identification | Back Directory | [Name]
GLP-1 receptor agonist 1 | [CAS]
2212020-52-3 | [Synonyms]
LY3502970
Orforglipron
GLP-1 receptor agonist 1 USP/EP/BP
1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy... | [Molecular Formula]
C48H48F2N10O5 | [MOL File]
2212020-52-3.mol | [Molecular Weight]
882.97 |
| Chemical Properties | Back Directory | [density ]
1.50±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 125 mg/mL (141.57 mM) | [form ]
Solid | [pka]
7.33±0.20(Predicted) | [color ]
Off-white to light yellow | [InChIKey]
USUWIEBBBWHKNI-BBGRWQLENA-N |
| Hazard Information | Back Directory | [Description]
Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67. | [Uses]
Glucagon-like peptide-1 (GLP-1) agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat type 2 diabetes mellitus and, in some cases, obesity. |
|
|